

WHAT IS CLAIMED IS:

1. A compound having the structure



.

2. A pharmaceutically acceptable salt of a compound having the structure



.

3. The pharmaceutically acceptable salt according to claim 2, which is a monohydrochloride salt.

4. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

5. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 2 and a pharmaceutically acceptable carrier or diluent.

6. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 3 and a pharmaceutically acceptable carrier or diluent.

7. The compound according to claim 1 for use in therapy.

8. The pharmaceutically acceptable salt according to claim 2 for use in therapy.

9. The pharmaceutically acceptable salt according to claim 3 for use in therapy.

10. The pharmaceutical composition according to claim 4 for use in therapy.

11. The pharmaceutical composition according to claim 5 for use in therapy.

12. The pharmaceutical composition according to claim 6 for use in therapy.

13. Use of the compound according to claim 1 in the manufacture of a medicament for treating systemic lupus erythematosus in a patient.

14. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating systemic lupus erythematosus in a patient.

15. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating systemic lupus erythematosus in a patient.

16. Use of the compound according to claim 1 in the manufacture of a medicament for treating psoriasis in a patient.

17. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating psoriasis in a patient.

18. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating psoriasis in a patient.

19. Use of the compound according to claim 1 in the manufacture of a medicament for treating psoriatic arthritis in a patient.

20. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating psoriatic arthritis in a patient.

21. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating psoriatic arthritis in a patient.

22. Use of the compound according to claim 1 in the manufacture of a medicament for treating lupus nephritis in a patient.

23. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating lupus nephritis in a patient.

24. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating lupus nephritis in a patient.

25. Use of the compound according to claim 1 in the manufacture of a medicament for treating Sjögren’s syndrome in a patient.

26. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating Sjögren’s syndrome in a patient.

27. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating Sjögren's syndrome in a patient.

28. Use of the compound according to claim 1 in the manufacture of a medicament for treating inflammatory bowel disease in a patient.

29. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating inflammatory bowel disease in a patient.

30. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating inflammatory bowel disease in a patient.

31. Use of the compound according to claim 1 in the manufacture of a medicament for treating Crohn's disease in a patient.

32. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating Crohn's disease in a patient.

33. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating Crohn's disease in a patient.

34. Use of the compound according to claim 1 in the manufacture of a medicament for treating ankylosing spondylitis in a patient.

35. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating ankylosing spondylitis in a patient.

36. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating ankylosing spondylitis in a patient.

37. Use of a composition in the manufacture of a medicament for treating psoriasis in a subject, wherein the composition comprises the compound according to claim 1, wherein the composition is to be orally administered to the subject.

38. The use according to claim 37, wherein the composition is in the form of a tablet, a capsule, granules, a powder, or a liquid formulation.

39. The use according to claim 38, wherein the composition is in the form of a tablet.

40. The use according to claim 38, wherein the composition is in the form of a capsule.

41. The use according to claim 38, wherein the composition is in the form of granules.

42. The use according to claim 38, wherein the composition is in the form of a powder.

43. The use according to claim 38, wherein the composition is in the form of a liquid formulation.

44. The use according to claim 43, wherein the composition is in the form of a syrup.

45. The use according to claim 37, wherein the composition is to be orally administered to the subject 1 to 4 times per day.

46. The use according to claim 45, wherein the composition is in the form of a tablet.

47. Use of a tablet in the manufacture of a medicament for treating psoriasis in a subject, wherein the tablet comprises the compound according to claim 1, wherein the tablet is to be administered orally to the subject, 1 to 2 times per day.

48. The use according to claim 47, wherein one tablet per day is to be administered to the subject.

49. The use according to claim 47, wherein two tablets per day are to be administered to the subject.

50. Use of a tablet in the manufacture of a medicament for treating psoriasis in a subject, wherein the tablet comprises the pharmaceutically acceptable salt according to claim 2, wherein the tablet is to be orally administered to the subject, 1 to 2 times per day.

51. The use according to claim 50, wherein one tablet per day is to be administered to the subject.

52. The use according to claim 50, wherein two tablets per day are to be administered to the subject.